Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Newsworthy Abstract
Registration Required
No CME
On-Demand Video
Livestream
Back
Favorite
Post (Tweet)
Bruce E. Sands, MD, FACG
Icahn School of Medicine at Mount Sinai
Poster(s):
P4350 - Efficacy of Guselkumab vs Placebo In Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4351 - Efficacy and Safety of Long-Term Mirikizumab Treatment in Patients With Moderate to Severe Crohn’s Disease
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4352 - Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4353 - Impact of Prior Biologic Exposure on the Durability of Ozanimod Over 5 Years of Continuous Treatment in Patients With Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension Study
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4354 - Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4355 - Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4356 - Efficacy and Safety Profile of Etrasimod Was Not Impacted by Baseline Disease Activity: A Post Hoc Analysis of the ELEVATE UC Program
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4357 - Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 VIVID-1 Study
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4358 - Disease Characteristics Associated With Bowel Urgency in Crohn’s Disease: Results From the Phase 3 VIVID-1 Trial
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
P4359 - Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Ulcerative Colitis (UC): Results From the Open-Label Extension (OLE) Period of the Phase 2 ARTEMIS-UC Study
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
